Lupus & antiphospholipid syndrome
Predictive value of the adjusted Global Anti-Phospholipid Syndrome Score on clinical recurrence in APS patients: a longitudinal study
Authors' conclusion
Our data support the role of periodic (annual) monitoring of the aGAPSS score in predicting clinical recurrence in patients with APS.
Study context
- Population
- Patients with APS; Adjusted global APS score (aGAPSS) calculated at baseline and yearly for up to 6 years (minimum 3 years) or until just before the clinical event
- Participants
- 200 patients
- Exposure
- Average aGAPSS in patients with vs without clinical recurrence
- Outcome
- Recurrence of clinical manifestations by average aGAPSS over time
Methodological detailsCox regression analysis, multivariate analysis
- Cox regression analysis
- Multivariate analysis
Main finding
As reported in the abstract
Average aGAPSS
Recurrence
8.81
95% CI 7.53–10.08
No recurrence
6.38
95% CI 5.64–7.12
P = 0.001
Observational data: associations, not effects.
Further findings
| Outcome | Values | P value |
|---|---|---|
| Average aGAPSS, thrombotic vs obstetric recurrence | Thrombotic recurrence 9.48 (95% CI 8.14–10.82) · Obstetric recurrence 4.25 (95% CI 0.85–7.65) | P = 0.006 |
| Average aGAPSS, arterial vs venous thrombosis | Arterial thrombosis 10.66 (SD 5.48) | P = 0.01 |
The therapeutic range (TTR) in vitamin K antagonists (VKA)-treated patients, thrombosis recurrence vs none
- TTR not statistically different between patients with and without thrombosis recurrence
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Predictive value of the adjusted Global Anti-Phospholipid Syndrome Score on clinical recurrence in APS patients: a longitudinal study. Rheumatology (Oxford). Published 23 August 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →